Bio-Techne (TECH) Curent Deferred Tax Liability (2012 - 2013)

Bio-Techne (TECH) recorded quarterly Curent Deferred Tax Liability of $9.9 million in Q2 2013, down 1.23% quarter-over-quarter from $10.1 million in Q1 2013, and down 30.14% on a YoY basis from $14.2 million in Q2 2012.

Bio-Techne (TECH) Curent Deferred Tax Liability (2012 - 2013) Analysis & Trends

Bio-Techne's Curent Deferred Tax Liability history runs 2 years deep, the most recent figure standing at $9.9 million for Q2 2013.

  • In Q2 2013, Curent Deferred Tax Liability fell 30.14% year-over-year to $9.9 million; the TTM figure through Jun 2013 stood at $9.9 million (down 30.14% YoY), while the FY2013 annual figure was $9.9 million, down 30.14% from the prior year.
  • Curent Deferred Tax Liability was $9.9 million for Q2 2013 at Bio-Techne, down from $10.1 million in the prior quarter.
  • In the past five years, Curent Deferred Tax Liability ranged from a high of $14.2 million in Q2 2012 to a low of $4.2 million in Q4 2012.
Generated on {Timestamp} © BusinessQuant.com
Generated on {Timestamp} Powered by BusinessQuant Logo

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Curent Deferred Tax (Qtr)
1 Alterity Therapeutics 925,601.88 Bn 925,601.85 Bn - -
2 Belite Bio 58,560.00 Bn 58,560.00 Bn - -
3 Quantum Biopharma 17,284.41 Bn 17,284.40 Bn - -
4 Legend Biotech 2,809.00 Bn 2,808.71 Bn 242.10 Mn -
5 Evaxion A 1,334.43 Bn 1,334.42 Bn - -
6 Akari Therapeutics 1,312.27 Bn 1,312.26 Bn - -
7 Psyence Biomedical 212.16 Bn 212.16 Bn - -
8 Vertex Pharmaceuticals 114.83 Bn 107.58 Bn 2.59 Bn -
9 Abivax 91.96 Bn 91.96 Bn - -
10 Bio-Techne 9.04 Bn 8.83 Bn 208.29 Mn -

Historic Data

Download Data
DateValue
Jun 30, 2013 9.94 Mn
Jun 30, 2013 9.94 Mn
Mar 31, 2013 10.07 Mn
Mar 31, 2013 10.07 Mn
Dec 31, 2012 4.21 Mn
Dec 31, 2012 4.21 Mn
Sep 30, 2012 6.17 Mn
Sep 30, 2012 6.17 Mn
Jun 30, 2012 14.23 Mn
Jun 30, 2012 14.23 Mn
Mar 31, 2012 4.26 Mn
Mar 31, 2012 4.26 Mn